Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. (CHRS) on May 10, 2022, covering events occurring on May 4, 2022. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Charles Newton to the Board of Directors to fill a vacancy. Mr. Newton was appointed as a Class I director with a term expiring at the 2024 annual meeting of stockholders. He was also appointed as a member of the Audit Committee.
Management Commentary and Compensation
- Background: Mr. Newton is currently the Chief Financial Officer of Lyell Immunopharma. His prior experience includes senior roles in healthcare investment banking at BofA Securities, Credit Suisse, and Morgan Stanley, where he advised on approximately $200 billion in M&A and raised nearly $60 billion in capital.
- Compensation: As a non-employee director, Mr. Newton will receive an annual cash retainer of $50,000.
- Equity Grant: He received an option to purchase 54,000 shares of common stock under the 2014 Equity Incentive Award Plan. The exercise price equals the closing price on the appointment date. The option vests in substantially equal monthly installments over three years.
- Indemnification: The Company expects to enter into its standard form of indemnification agreement with Mr. Newton.
Investor Verification Checklist
- Verify the current share price on May 4, 2022, to determine the exercise price of the 54,000 stock options granted to Mr. Newton.
- Review the Company's 2014 Equity Incentive Award Plan to confirm the total pool of shares available for issuance.
- Confirm the composition of the Audit Committee following Mr. Newton's appointment to ensure compliance with independence requirements.
- Check subsequent filings for any changes to the Board composition or Mr. Newton's service status.